Dramatic Growth in Cancer Rates Predicted for Elderly, Minorities

Publication
Article
OncologyONCOLOGY Vol 23 No 6
Volume 23
Issue 6

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly (67% increase) and minority (100% increase) populations, according to research from The University of Texas M. D. Anderson Cancer Center.

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly (67% increase) and minority (100% increase) populations, according to research from The University of Texas M. D. Anderson Cancer Center. The study was based on statistics from the US Census Bureau and the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) registry.

Articles in this issue
Mate (Ilex paraguariensis)
Mate (Ilex paraguariensis)
Therapeutic Options in Relapsed or Refractory Diffuse Large B-cell Lymphoma: Part 1
Key Questions for Perioperative Chemotherapy in Resectable Lung Cancer
Adjuvant or Induction Cisplatin-Based Chemotherapy for Operable Lung Cancer
Adjuvant vs Neoadjuvant Chemotherapy in Resectable NSCLC: Is That the Real Question?
Pregnancy and Fertility With Breast Cancer: What Are the Options?
Breast Cancer in Women Under 40
Complexities of Adjuvant Endocrine Therapy in Young Premenopausal Women
Breast Cancer in Young Women: Clinical Decision-Making in the Face of Uncertainty
NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus
Dramatic Growth in Cancer Rates Predicted for Elderly, Minorities
Penn Study Examines Power of Exercise to Prevent Breast Cancer
The Pathway Ahead in Melanoma Trials
Treating Metastatic Melanoma: Further Considerations
Treatment of Metastatic Melanoma: An Overview
Treatment of Metastatic Melanoma: An Overview
Recent Videos
Related Content
3 Things You Should Know About Hemolytic Anemias

3 Things You Should Know About Hemolytic Anemias

Catherine M. Broome, MD;Sigbjørn Berentsen, MD, PhD;Caroline Piatek, MD;Ilene Ceil Weitz, MD
December 20th 2024
Article

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
December 10th 2024
Article

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024
Article

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024
Article

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.